Agree..the institutions paid $25+ and they were oversubscribed ! SRPT is unlikely to go any lower than low 20's. A likely scenario is FDA may ask SRPT to do a controlled but short trial (aka expanded PI) in line with their new paradigm shift of supporting pathways for innovative drugs. Eteplirsen definitely qualifies in that regard.
Market Data 
Markets 
AI
